One Capital Management LLC Increases Stock Position in Halozyme Therapeutics, Inc. $HALO

One Capital Management LLC boosted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 39.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,806 shares of the biopharmaceutical company’s stock after purchasing an additional 13,248 shares during the quarter. One Capital Management LLC’s holdings in Halozyme Therapeutics were worth $3,150,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Clark Capital Management Group Inc. raised its stake in Halozyme Therapeutics by 14.4% in the third quarter. Clark Capital Management Group Inc. now owns 202,965 shares of the biopharmaceutical company’s stock valued at $14,885,000 after purchasing an additional 25,582 shares in the last quarter. Intech Investment Management LLC raised its stake in Halozyme Therapeutics by 46.0% in the third quarter. Intech Investment Management LLC now owns 148,667 shares of the biopharmaceutical company’s stock valued at $10,903,000 after purchasing an additional 46,850 shares in the last quarter. Allworth Financial LP raised its stake in Halozyme Therapeutics by 322.5% in the third quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company’s stock valued at $2,914,000 after purchasing an additional 30,331 shares in the last quarter. ING Groep NV purchased a new stake in Halozyme Therapeutics in the third quarter valued at approximately $6,652,000. Finally, Element Squared LLC purchased a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $1,193,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Trading Down 2.7%

HALO stock opened at $66.28 on Wednesday. The company has a market capitalization of $7.86 billion, a PE ratio of 23.84, a price-to-earnings-growth ratio of 0.28 and a beta of 0.88. Halozyme Therapeutics, Inc. has a one year low of $51.06 and a one year high of $82.22. The company’s 50 day moving average price is $66.24 and its two-hundred day moving average price is $68.75. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $1.54 by $0.06. The firm had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business’s revenue was up 42.2% compared to the same quarter last year. During the same period last year, the firm posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, analysts predict that Halozyme Therapeutics, Inc. will post 7.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on HALO shares. Benchmark raised their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Morgan Stanley decreased their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Wells Fargo & Company lifted their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 19th. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $80.67.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $64.24, for a total value of $1,284,800.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at $49,322,187.20. The trade was a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Monday, March 9th. The shares were sold at an average price of $67.80, for a total transaction of $1,356,000.00. Following the completion of the sale, the chief operating officer owned 14,366 shares in the company, valued at approximately $974,014.80. This trade represents a 58.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 92,107 shares of company stock worth $6,212,534. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.